Drug lobby wants clearer FDA rules for diet pills
WASHINGTON (Reuters) – The pharmaceutical industry may stop investing in medicines to treat diseases like diabetes or obesity without more explicit guidelines from U.S. regulators, the chairman of the drug trade group said on Thursday.
The Food and Drug Administration must approve any medical products sold in the United States, but drug companies say they cannot always predict how the agency weighs risks and benefits for medicines that could be widely used. Read more